3-D model of solid tumors explains cancer evolution

August 26, 2015, Harvard University
A three-dimensional model of a tumor showing cell types in varying colors. Credit: Bartek Waclaw and Martin Nowak

They're among the most powerful tools for shedding new light on cancer growth and evolution, but mathematical models of the disease for years have faced an either/or stand off.

Though models have been developed that capture the spatial aspects of tumors, those models typically don't study genetic changes. Non-spatial models, meanwhile, more accurately portray tumors' evolution, but not their three-dimensional structure.

A collaboration between Harvard, Edinburgh, and Johns Hopkins Universities including Martin Nowak, Director of the Program for Evolutionary Dynamics and Professor of Mathematics and of Biology at Harvard, has now developed the first model of solid tumors that reflects both their three-dimensional shape and genetic evolution. The new model explains why have a surprising number of genetic mutations in common, how driver mutations spread through the whole tumor and how drug resistance evolves. The study is described in an August 26 paper in Nature.

"Previously, we and others have mostly used non-spatial models to study cancer evolution," Nowak said. "But those models do not describe the spatial characteristics of solid tumors. Now, for the first time, we have a computational model that can do that."

A key insight of the new model, Nowak said, is the ability for to migrate locally.

"Cellular mobility makes cancers grow fast, and it makes cancers homogenous in the sense that cancer cells share a common set of mutations. It is responsible for the rapid evolution of drug resistance," Nowak said. "I further believe that the ability to form metastases, which is what actually kills patients, is a consequence of selection for local migration."

Nowak and colleagues, including Bartek Waclaw of the University of Edinburgh, who is the first author of the study, Ivana Bozic of Harvard University and Bert Vogelstein of Johns Hopkins University, set out to improve on past models, because they were unable to answer critical questions about the spatial architecture of genetic evolution.

"The majority of the mathematical models in the past counted the number of cells that have particular mutations, but not their spatial arrangement," Nowak said. Understanding that spatial structure is important, he said, because it plays a key role in how tumors grow and evolve.

In a spatial model cells divide only if they have the space to do so. This results in slow growth unless cells can migrate locally.

"By giving cells the ability to migrate locally," Nowak said, "individual cells can always find new space where they can divide.

The result isn't just faster tumor growth, but a model that helps to explain why cancer cells share an unusually high number of , and how drug resistance can rapidly evolve in tumors.

As they divide, all cells - both healthy and cancerous - accumulate mutations, Nowak said, and most are so called "passenger" mutations that have little effect on the cell.

In cancer cells, however, approximately 5 percent are what scientists call "driver" mutations - changes that allow cells to divide faster or live longer. In addition to rapid tumor growth, those mutations carry some previous passenger mutations forward, and as a result cancer cells often have a surprising number of mutations in common.

Similarly, emerges when cells mutate to become resistant to a particular treatment. While targeted therapies wipe out nearly all other cells, the few resistant cells begin to quickly replicate, causing a relapse of the cancer.

"This migration ability helps to explain how driver are able to dominate a tumor, and also why targeted therapies fail within a few months as resistance evolves," Nowak said. "So what we have is a computer for , and it's this local migration that is of crucial importance."

"Our approach does not provide a miraculous cure for cancer." said Bartek Waclaw, "However, it suggests possible ways of improving cancer therapy. One of them could be targeting cellular motility (that is local migration) and not just growth as standard therapies do."

Explore further: Cancer therapy 'tumor sanctuaries' and the breeding ground of resistance

More information: A spatial model predicts that dispersal and cell turnover limit intratumor heterogeneity, Nature, DOI: 10.1038/nature14971

Related Stories

Cancer therapy 'tumor sanctuaries' and the breeding ground of resistance

March 19, 2015
Tumors acquiring resistance is one of the major barriers to successful cancer therapy. Feng Fu, Sebastian Bonhoeffer (ETH Zurich) and their collaborator Martin Nowak (Harvard) use mathematical models to characterize how important ...

A better way to personalize bladder cancer treatments

August 14, 2015
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took bladder ...

Transforming cancer treatment: Multidrug strategy emerges from new research

July 11, 2012
A Harvard researcher studying the evolution of drug resistance in cancer says that, in a few decades, “many, many cancers could be manageable.”

Advanced cancers destined to recur after treatment with single drugs that 'target' tumor cells: study

June 13, 2012
Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, ...

New plan of attack in cancer fight

July 19, 2013
New research conducted by Harvard scientists is laying out a road map to one of the holy grails of modern medicine: a cure for cancer.

Integrative approaches key to understanding cancer, developing therapies

March 27, 2015
Moffitt Cancer Center researchers are using integrative approaches to study cancer by combining mathematical and computational modeling with experimental and clinical data. The use of integrative approaches enables scientists ...

Recommended for you

A small, daily dose of Viagra may reduce colorectal cancer risk

March 19, 2018
A small, daily dose of Viagra significantly reduces colorectal cancer risk in an animal model that is genetically predetermined to have the third leading cause of cancer death, scientists report.

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.